SEARCH

SEARCH BY CITATION

References

  • Agadjanyan M. G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., Saing T. and Cribbs D. H. (2005) Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174, 15801586.
  • Aguado-Llera D., Arilla-Ferreiro E., Campos-Barros A., Puebla-Jimenez L. and Barrios V. (2005) Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of beta-amyloid-treated rats. J. Neurochem. 92, 607615.
  • Allen R. G. and Tresini M. (2000) Oxidative stress and gene regulation. Free Radic. Biol. Med. 28, 463499.
  • Alzheimer A. (1907) Uber eine eijenartige Erkrankung der Hirnride. Allg. Z. Psychiatr. 64, 146148.
  • Andersen O. M., Reiche J., Schmidt V., et al. (2005) Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl Acad. Sci. U S A 102, 13 46113 466.
  • Andersen O. M., Schmidt V., Spoelgen R., et al. (2006) Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry 45, 26182628.
  • Anderson J. J., Holtz G., Baskin P. P., et al. (2005) Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem. Pharmacol. 69, 689698.
  • Arbel M., Yacoby I. and Solomon B. (2005) Inhibition of amyloid precursor protein processing by {beta}-secretase through site-directed antibodies. Proc. Natl Acad. Sci. U S A 102, 77187723.
  • Arispe N., Rojas E. and Pollard H. B. (1993) Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl Acad. Sci. U S A 90, 567571.
  • Arlt S., Beisiegel U. and Kontush A. (2002) Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease. Curr. Opin. Lipidol. 13, 289294.
  • Atwood C. S., Moir R. D., Huang X., Scarpa R. C., Bacarra N. M., Romano D. M., Hartshorn M. A., Tanzi R. E. and Bush A. I. (1998) Dramatic aggregation of Alzheimer Aβ by Cu (II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273, 12 81712 826.
  • Auld D. S., Kornecook T. J., Bastianetto S. and Quirion R. (2002) Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 68, 209245.
  • Bales K. R., Verina T., Dodel R. C., et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17, 263264.
  • Bano S. and Parihar M. S. (1997) Reduction of lipid peroxidation in different brain regions by a combination of alpha-tocopherol and ascorbic acid. J. Neural Transm 104, 12771286.
  • Bard F., Cannon C., Barbour R., et al. (2000) Peripherally administered antibodies against amyloid β peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916919.
  • Barnham K. J., McKinstry W. J., Multhaup G., et al. (2003a) Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J. Biol. Chem. 278, 17 40117 407.
  • Barnham K. J., Ciccotosto G. D., Tickler A. K., et al. (2003b) Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 278, 42 95942 965.
  • Barnham K. J., Haeffner F., Ciccotosto G. D., et al. (2004a) Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J. 18, 14271429.
  • Barnham K. J., Masters C. L. and Bush A. I. (2004b) Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 3, 205214.
  • Barrow C. J. (2002) Advances in the development of Abeta-related therapeutic strategies for Alzheimer's disease. Drug News Perspect. 15, 102109.
  • Barten D. M., Guss V. L., Corsa J. A., et al. (2005) Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J. Pharmacol. Exp. Ther. 312, 635643.
  • Bayer T. A., Schafer S., Simons A., et al. (2003) Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 100, 14 18714 192.
  • Beffert U. and Poirier J. (1998) ApoE associated with lipid has a reduced capacity to inhibit beta-amyloid fibril formation. Neuroreport 9, 33213323.
  • Beher D., Clarke E. E., Wrigley J. D., Martin A. C., Nadin A., Churcher I. and Shearman M. S. (2004) Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site-evidence for an allosteric mechanism. J. Biol. Chem. 279, 43 41943 426.
  • Behl C. and Holsboer F. (1999) The female sex hormone oestrogen as a neuroprotectant. Trends Pharmacol. Sci. 20, 441444.
  • Belluti F., Rampa A., Piazzi L., et al. (2005) Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. J. Med. Chem. 48, 44444456.
  • Bentahir M., Nyabi O., Verhamme J., Tolia A., Horre K., Wiltfang J., Esselmann H. and De Strooper B. (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J. Neurochem. 96, 732742.
  • Bernheimer A. W., Robinson W. G., Linder R., Mullins D., Yip Y. K., Cooper N. S., Seidman I. and Uwajima T. (1987) Toxicity of enzymically-oxidized low-density lipoprotein. Biochem. Biophys. Res. Commun. 148, 260266.
  • Bertram L., Blacker D., Mullin K., et al. (2000) Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290, 23022303.
  • Blanchard B. J., Chen A., Rozeboom L. M., Stafford K. A., Weigele P. and Ingram V. M. (2004) Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc. Natl. Acad. Sci. U.S.A. 101, 14 32614 332.
  • Boedker M., Boetkjaer A., Bazan N. G., Cui J. G., Zhao Y., Pelaez R. P. and Lukiw W. J. (2005) Budesonide epimer R., LAU-8080 and phenyl butyl nitrone synergistically repress cyclooxygenase-2 induction in [IL-1beta+Abeta42]-stressed human neural cells. Neurosci. Lett. 380, 176180.
  • Borchardt T., Camakaris J., Cappai R., Masters C. L., Beyreuther K. and Multhaup G. (1999) Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. Biochem. J. 344, Part 2, 461467.
  • Bozzao A., Floris R., Baviera M. E., Apruzzese A. and Simonetti G. (2001) Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. AJNR Am. J. Neuroradiol. 22, 10301036.
  • Braak H. and Braak E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82, 239259.
  • Brendza R. P., Bacskai B. J., Cirrito J. R., et al. (2005) Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest. 115, 428433.
  • Brown G. C. and Bal-Price A. (2003) Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol. 27, 325355.
  • Bush A. I. (2002) Metal complexing agents as therapies for Alzheimer's disease. Neurobiol. Aging 23, 10311038.
  • Bush A. I. (2003) The metallobiology of Alzheimer's disease. Trends Neurosci. 26, 207214.
  • Bush A. I., Masters C. L. and Tanzi R. E. (2003) Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. Proc. Natl. Acad. Sci. U.S.A. 100, 11931194.
  • Butterfield D. A. and Boyd-Kimball D. (2004) Amyloid beta-peptide (1–42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol. 14, 426432.
  • Butterfield D. A., Drake J., Pocernich C. and Castegna A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7, 548554.
  • Byrne E. (2002) Does mitochondrial respiratory chain dysfunction have a role in common neurodegenerative disorders? J. Clin. Neurosci. 9, 497501.
  • Caccamo A., Oddo S., Billings L. M., Green K. N., Martinez-Coria H., Fisher A. and LaFerla F. M. (2006) M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49, 671682.
  • Cadenas E. and Davies K. J. (2000) Mitochondrial free radical generation, oxidative stress, and aging. Free Radic. Biol. Med. 29, 222230.
  • Camargo E. E. (2001) Brain SPECT in neurology and psychiatry. J. Nucl. Med. 42, 611623.
  • Cappai R. and White A. R. (1999) Amyloid beta. Int. J. Biochem. Cell Biol. 31, 885889.
  • Caraci F., Chisari M., Frasca G., et al. (2005) Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against beta-amyloid toxicity. Brain Res. 1047, 3037.
  • Chang C. Y. and Silverman D. H. (2004) Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease. Expert Rev. Mol. Diagn. 4, 6369.
  • Chang J. Y., Chavis J. A., Liu L. Z. and Drew P. D. (1998) Cholesterol oxides induce programmed cell death in microglial cells. Biochem. Biophys. Res. Commun. 249, 817821.
  • Chauhan N. B., Siegel G. J. and Feinstein D. L. (2005) Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576. Neuropharmacology 48, 93104.
  • Cherny R. A., Legg J. T., McLean C. A., et al. (1999) Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J. Biol. Chem. 274, 23 22323 228.
  • Cherny R. A., Atwood C. S., Xilinas M. E., et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665676.
  • Chetelat G. and Baron J. C. (2003) Early diagnosis of Alzheimer's disease; contribution of structural neuroimaging. Neuroimage 18, 525541.
  • Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A. Y., Seubert P., Vigo-Pelfrey C., Lieberburg I. and Selkoe D. J. (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360, 672674.
  • Cole S. L., Grudzien A., Manhart I. O., Kelly B. L., Oakley H. and Vassar R. (2005) Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J. Biol. Chem. 280, 18 75518 770.
  • Coleman R. E. (2005) Positron emission tomography diagnosis of Alzheimer's disease. Neuroimaging Clin. N. Am. 15, 837846.
  • Comery T. A., Martone R. L., Aschmies S., et al. (2005) Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 25, 88988902.
  • Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L. and Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921923.
  • Cordle A. and Landreth G. (2005) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J. Neurosci. 25, 299307.
  • Cotman C. W., Poon W. W., Rissman R. A. and Blurton-Jones M. (2005) The role of caspase cleavage of tau in Alzheimer disease neuropathology. J. Neuropathol. Exp. Neurol. 64, 104112.
  • Cui Z., Lockman P. R., Atwood C. S., Hsu C. H., Gupte A., Allen D. D. and Mumper R. J. (2005) Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm. 59, 263272.
  • Curtain C. C., Ali F., Volitakis I., et al. (2001) Alzheimer's disease amyloid-β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276, 20 46620 473.
  • Dash P. K., Moore A. N. and Orsi S. A. (2005) Blockade of gamma-secretase activity within the hippocampus enhances long-term memory. Biochem. Biophys. Res. Commun. 338, 777782.
  • DeMattos R. B., Bales K. R., Cummins D. J., Dodart J. C., Paul S. M. and Holtzman D. M. (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98, 88508855.
  • Derkinderen P., Scales T. M., Hanger D. P., et al. (2005) Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J. Neurosci. 25, 65846593.
  • De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K. and Van Leuven F. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387390.
  • Dickerson B. C., Goncharova I., Sullivan M. P., Forchetti C., Wilson R. S., Bennett D. A., Beckett L. A. and DeToledo-Morrell L. (2001) MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol. Aging 22, 747754.
  • Dizdaroglu M. (1992) Oxidative damage to DNA in mammalian chromatin. Mutat. Res. 275, 331342.
  • Dong J., Atwood C. S., Anderson V. E., Siedlak S. L., Smith M. A., Perry G. and Carey P. R. (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42, 27682773.
  • Doraiswamy P. M., Chen J. G. and Charles H. C. (2000) Brain magnetic resonance spectroscopy: role in assessing outcomes in Alzheimer's disease. CNS Drugs 14, 457472.
  • Du, A. T., Schuff N., Amend D., et al. (2001) Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 71, 441447.
  • Duff K. and Planel E. (2005) Untangling memory deficits. Nat. Med. 11, 826827.
  • Dulubova I., Ho A., Huryeva I., Sudhof T. C. and Rizo J. (2004) Three-dimensional structure of an independently folded extracellular domain of human amyloid-beta precursor protein. Biochemistry 43, 95839588.
  • Echeverria V., Clerman A. and Doré S. (2005) Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. Eur. J. Neurosci. 22, 21992206.
  • Eckert G. P., Wood W. G. and Muller W. E. (2005) Membrane disordering effects of beta-amyloid peptides. Subcell. Biochem. 38, 319337.
  • Eckman E. A. and Eckman C. B. (2005) Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 33, 11011105.
  • Emilien G., Beyreuther K., Masters C. L. and Maloteaux J. M. (2000) Prospects for pharmacological intervention in Alzheimer disease. Arch. Neurol 57, 454459.
  • Van Es J. H., Van Gijn M. E., Riccio O., et al. (2005) Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959963.
  • Farias G. G., Godoy J. A., Vazquez M. C., Adani R., Meshulam H., Avila J., Amitai G. and Inestrosa N. C. (2005) The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol. Dis. 18, 176183.
  • Fassbender K., Simons M., Bergmann C., et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 98, 58565861.
  • Frenkel D., Maron R., Burt D. S. and Weiner H. L. (2005) Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 115, 24232433.
  • Gabbita S. P., Lovell M. A. and Markesbery W. R. (1998) Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem. 71, 20342040.
  • Gaeta A. and Hider R. C. (2005) The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br. J. Pharmacol. 146, 10411059.
  • Games D., Adams D., Alessandrini R., et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523527.
  • Gibson T. J. and Murphy R. M. (2005) Design of peptidyl compounds that affect beta-amyloid aggregation: importance of surface tension and context. Biochemistry 44, 88988907.
  • Gilman S., Koller M., Black R. S., et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 15531562.
  • Glenner G. G. and Wong C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885890.
  • Good P. F., Werner P., Hsu A., Olanow C. W. and Perl D. P. (1996) Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol 149, 2128.
  • Götz J., Chen F., Van Dorpe J. and Nitsch R. M. (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 14911495.
  • Green P. S., Bales K., Paul S. and Bu G. (2005) Estrogen therapy fails to alter amyloid deposition in the PDAPP model of Alzheimer's disease. Endocrinology 146, 27742781.
  • Griffin W. S., Stanley L. C., Ling C., White L., MacLeod V., Perrot L. J., White C. L. 3rd and Araoz C. (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 86, 76117615.
  • Gundersen E., Fan K., Haas K., et al. (2005) Molecular-modeling based design, synthesis, and activity of substituted piperidines as gamma-secretase inhibitors. Bioorg. Med. Chem. Lett. 15, 18911894.
  • Hanessian S., Yun H., Hou Y., et al. (2005) Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J. Med. Chem. 48, 51755190.
  • Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353356.
  • Hardy J., Duff K., Hardy K. G., Perez-Tur J. and Hutton M. (1998) Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat. Neurosci. 1, 355358.
  • Harper J. D. and Lansbury P. T. Jr (1997) Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385407.
  • Harper J. D., Wong S. S., Lieber C. M., and Lansbury P. T. Jr (1999) Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38, 89728980.
  • Hartman R. E., Izumi Y., Bales K. R., Paul S. M., Wozniak D. F. and Holtzman D. M. (2005) Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci. 25, 62136220.
  • Hemming M. L. and Selkoe D. J. (2005) Amyloid {beta}-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J. Biol. Chem. 280, 37 64437 650.
  • Hennessy E. J. and Buchwald S. L. (2005) Synthesis of 4,5-dianilinophthalimide and related analogues for potential treatment of Alzheimer's disease via palladium-catalyzed amination. J. Org. Chem. 70, 73717375.
  • Henry A., Li Q. X., Galatis D., Hesse L., Multhaup G. and Beyreuther K., Masters C. L. and Cappai R. (1998) Inhibition of platelet activation by the Alzheimer's disease amyloid precursor protein. Br. J. Haematol 103, 402415.
  • Higuchi M., Yanai K., Okamura N., et al. (2000) Histamine H (1) receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience 99, 721729.
  • Higuchi M., Iwata N., Matsuba Y., Sato K., Sasamoto K. and Saido T. C. (2005) (19)F and (1)H MRI detection of amyloid beta plaques in vivo. Nat. Neurosci. 8, 527533.
  • Höglund K., Syversen S., Lewczuk P., Wallin A., Wiltfang J. and Blennow K. (2005a) Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease. Exp Brain Res. 164, 205214.
  • Höglund K., Thelen K. M., Syversen S., et al. (2005b) The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 19, 256265.
  • Hsia A. Y., Masliah E., McConlogue L., et al. (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U.S.A. 96, 32283233.
  • Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F. and Cole G. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99102.
  • Hu J., LaDu M. J. and Van Eldik L. J. (1998) Apolipoprotein E attenuates beta-amyloid-induced astrocyte activation. J. Neurochem. 71, 16261634.
  • Huang X., Atwood C. S., Moir R. D., Hartshorn M. A., Vonsattel J. P., Tanzi R. E. and Bush A. I. (1997) Zinc-induced Alzheimer's Abeta1–40 aggregation is mediated by conformational factors. J. Biol. Chem. 272, 26 46426 470.
  • Huang D. Luthi U., Kolb P., Edler K., Cecchini M., Audetat S., Barberis A. and Caflisch A. (2005) Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations. J. Med. Chem. 48, 51085111.
  • Hutton M., Lendon C. L., Rizzu P., et al. (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702705.
  • Hynes T. R., Randal M., Kennedy L. A., Eigenbrot C. and Kossiakoff A. A. (1990) X-ray crystal structure of the protease inhibitor domain of Alzheimer's amyloid beta-protein precursor. Biochemistry 29, 10 01810 022.
  • Ibach B., Haen E., Marienhagen J. and Hajak G. (2005) Clioquinol treatment in familiar early onset of Alzheimer's disease: a case report. Pharmacopsychiatry 38, 178179.
  • Irizarry M. C., Soriano F., McNamara M., Page K. J., Schenk D., Games D. and Hyman B. T. (1997) Abeta deposition is associated with neurophil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17, 70537059.
  • Jankowsky J. L., Slunt H. H., Gonzales V., et al. (2005) Persistent amyloidosis following suppression of abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2, e355.
  • Jantzen P. T., Connor K. E., DiCarlo G., Wenk G. L., Wallace J. L., Rojiani A. M., Coppola D., Morgan D. and Gordon M. N. (2002) Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22, 22462254.
  • Janus C., Pearson J., McLaurin J., et al. (2000) Aβ-peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979982.
  • Jessen F., Block W., Traber F., Keller E., Flacke S., Papassotiropoulos A., Lamerichs R., Heun R. and Schild H. H. (2000) Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55, 684688.
  • Jhamandas J. H., Wie M. B., Harris K., MacTavish D. and Kar S. (2005) Fucoidan inhibits cellular and neurotoxic effects of beta-amyloid (A beta) in rat cholinergic basal forebrain neurons. Eur. J. Neurosci. 21, 26492659.
  • Jobst K. A., Smith A. D., Szatmari M., et al. (1992) Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 340, 11791183.
  • Jobst K. A., Barnetson L. P. and Shepstone B. J. (1998) Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R. criteria, SPECT, x-ray CT, and Apo E4 in medial temporal lobe dementias: Oxford Project to Investigate Memory and Aging. Int. Psychogeriatr. 10, 271302.
  • Jordan J., Galindo M. F., Miller R. J., Reardon C. A., Getz G. S. and LaDu M. J. (1998) Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J. Neurosci. 18, 195204.
  • Kagan B. L., Hirakura Y., Azimov R., Azimova R. and Lin M. C. (2002) The channel hypothesis of Alzheimer's disease: current status. Peptides 23, 13111315.
  • Kalaria R. N. (2002) Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc. Dis. 13, 4852.
  • Kanapathipillai M., Lentzen G., Sierks M. and Park C. B. (2005) Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer's beta-amyloid. FEBS Lett. 579, 47754780.
  • Kang J., Lemaire H. G., Unterbeck A., Salbaum J. M., Masters C. L., Grzeschik K. H., Multhaup G., Beyreuther K. and Muller-Hill B. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733736.
  • Kantarci K., Jack C. R., Xu Y. C., et al. (2001) Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology 219, 101107.
  • Kawahara M. (2004) Disruption of calcium homeostasis in the pathogenesis of Alzheimer's disease and other conformational diseases. Curr. Alzheimer Res. 1, 8795.
  • Keller J. N., Pang Z., Geddes J. W., Begley J. G., Germeyer A., Waeg G. and Mattson M. P. (1997) Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 69, 273284.
  • Kepe V., Barrio J. R., Huang S. C., et al. (2006) Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc. Natl. Acad. Sci. U.S.A. 103, 702707.
  • Kerr M. L. and Small D. H. (2005) Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development. J. Neurosci. Res. 80, 151159.
  • Killiany R. J., Hyman B. T., Gomez-Isla T., Moss M. B., Kikinis R., Jolesz F., Tanzi R., Jones K. and Albert M. S. (2002) MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 58, 11881196.
  • Kimberly W. T., Xia W., Rahmati T., Wolfe M. S. and Selkoe D. J. (2000) The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. J. Biol. Chem. 275, 31733178.
  • Kimura M., Akasofu S., Ogura H. and Sawada K. (2005) Protective effect of donepezil against Abeta (1–40) neurotoxicity in rat septal neurons. Brain Res. 1047, 7284.
  • Klunk W. E., Wang Y., Huang G. F., et al. (2003) The binding of 2-(4′-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J. Neurosci. 23, 20862092.
  • Klunk W. E., Engler H., Nordberg A., et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306319.
  • Klyubin I., Walsh D. M., Lemere C. A., et al. (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 11, 556561.
  • Kornacker M. G., Lai Z., Witmer M., et al. (2005) an inhibitor binding pocket distinct from the catalytic active site on human beta-APP cleaving enzyme. Biochemistry 44, 11 56711 573.
  • Kruman I. I. and Mattson M. P. (1999) Pivotal role of mitochondrial calcium uptake in neural cell apoptosis and necrosis. J. Neurochem. 72, 529540.
  • Lambourne S. L., Sellers L. A., Bush T. G., Choudhury S. K., Emson P. C., Suh Y. H. and Wilkinson L. S. (2005) Increased tau phosphorylation on mitogen-activated protein kinase consensus sites and cognitive decline in transgenic models for Alzheimer's disease and FTDP-17: evidence for distinct molecular processes underlying tau abnormalities. Mol. Cell Biol. 25, 278293.
  • Lanz T. A., Hosley J. D., Adams W. J. and Merchant K. M. (2004) Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). J. Pharmacol. Exp. Ther. 309, 4955.
  • Laras Y., Quelever G., Garino C., Pietrancosta N., Sheha M., Bihel F., Wolfe M. S. and Kraus J. L. (2005) Substituted thiazolamide coupled to a redox delivery system: a new gamma-secretase inhibitor with enhanced pharmacokinetic profile. Org. Biomol. Chem. 3, 612618.
  • Law A., Gauthier S. and Quirion R. (2001) Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res. Brain Res. Rev. 35, 7396.
  • Lecanu L., Yao W., Piechot A., Greeson J., Tzalis D. and Papadopoulos V. (2005) Identification, design, synthesis, and pharmacological activity of (4-ethyl-piperazin-1-yl)-phenylmethanone derivatives with neuroprotective properties against beta-amyloid-induced toxicity. Neuropharmacology 49, 8696.
  • Lee E. B., Leng L. Z., Lee V. M. and Trojanowski J. Q. (2005a) Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett. 579, 25642568.
  • Lee H. J., Seong Y. H., Bae K. H., et al. (2005b) Beta-secretase (BACE1) inhibitors from Sanguisorbae Radix. Arch. Pharm. Res. 28, 799803.
  • Lee J. Y., Cole T. B., Palmiter R. D., Suh S. W. and Koh J. Y. (2002) Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 99, 77057710.
  • Lee K. H., Shin B. H., Shin K. J., Kim D. J. and Yu J. (2005c) A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1–42). Biochem. Biophys. Res. Commun. 328, 816823.
  • Lee M., Bard F., Johnson-Wood K., Lee C., Hu K., Griffith S. G., Black R. S., Schenk D. and Seubert P. (2005d) Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann. Neurol. 58, 430435.
  • Lee S., Carson K., Rice-Ficht A. and Good T. (2005e) Hsp20, a novel alpha-crystallin, prevents Abeta fibril formation and toxicity. Protein Sci. 14, 593601.
  • Lee Y., Aono M., Laskowitz D., Warner D. S. and Pearlstein R. D. (2004) Apolipoprotein E protects against oxidative stress in mixed neuronal-glial cell cultures by reducing glutamate toxicity. Neurochem. Int. 44, 107118.
  • Lefranc-Jullien S., Lisowski V., Hernandez J. F., Martinez J. and Checler F. (2005) Design and characterization of a new cell-permeant inhibitor of the beta-secretase BACE1. Br. J. Pharmacol. 145, 228235.
  • Lemere C. A., Blusztajn J. K., Yamaguchi H., Wisniewski T., Saido T. C. and Selkoe D. J. (1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis 3, 1632.
  • De Leon M. J., DeSanti S., Zinkowski R., et al. (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging 27, 394401.
  • Lewis J., Dickson D. W., Lin W. L., et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 14871491.
  • Lewis S. J., Smith A. L., Neduvelil J. G., et al. (2005) A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core. Bioorg. Med. Chem. Lett. 15, 373378.
  • Lim G. P., Yang F., Chu T., et al. (2001) Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22, 983991.
  • Lim G. P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., Salem N., Frautschy S. A. Jr and Cole G. M. (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25, 30323040.
  • Lippa C. F., Nee L. E., Mori H. and St George-Hyslop P. (1998) Abeta-42 deposition precedes other changes in PS-1 Alzheimer's disease. Lancet 352, 11171118.
  • Liu G., Garrett M. R., Men P., Zhu X., Perry G. and Smith M. A. (2005) Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim. Biophys. Acta 1741, 246252.
  • Lockhart A., Judd L., Ye D. B., Merritt A. T., Lowe P. N., Morgenstern J. L., Hong G., Gee A. D. and Brown J. (2005) Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J. Biol. Chem. 280, 76777684.
  • Lovell M. A., Ehmann W. D., Butler S. M. and Markesbery W. R. (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45, 15941601.
  • Lovell M. A., Robertson J. D., Teesdale W. J., Campbell J. L. and Markesbery W. R. (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 4752.
  • Lovestone S. and Reynolds C. H. (1997) The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78, 309324.
  • Ma Q., Li Y., Du J., Liu H., Kanazawa K., Nemoto T., Nakanishi H. and Zhao Y. (2006) Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS. Peptides 27, 841849.
  • Mahdi F., Van Nostrand W. E. and Schmaier A. H. (1995) Protease nexin-2/amyloid beta-protein precursor inhibits factor Xa in the prothrombinase complex. J. Biol. Chem. 270, 23 46823 474.
  • Marambaud P., Zhao H. and Davies P. (2005) Resveratrol promotes clearance of Alzheimer's disease amyloid-{beta} peptides. J. Biol. Chem. 280, 37 37737 382.
  • Mark R. J., Hensley K., Butterfield D. A. and Mattson M. P. (1995) Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J. Neurosci. 15, 62396249.
  • Mark R. J., Fuson K. S. and May P. C. (1999) Characterization of 8-epiprostaglandin F2alpha as a marker of amyloid beta-peptide-induced oxidative damage. J. Neurochem. 72, 11461153.
  • Marques M. A. and Crutcher K. A. (2003) Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease. J. Mol. Neurosci. 20, 327337.
  • Marrazzo A., Caraci F., Salinaro E. T., Su T. P., Copani A. and Ronsisvalle G. (2005) Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. Neuroreport 16, 12231226.
  • Marshall J. R., Stimson E. R., Ghilardi J. R., Vinters H. V., Mantyh P. W. and Maggio J. E. (2002) Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. Bioconjug. Chem. 13, 276284.
  • Martins R. N., Harper C. G., Stokes G. B. and Masters C. L. (1986) Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J. Neurochem. 46, 10421045.
  • Masliah E., Hansen L., Adame A., et al. (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129131.
  • Masse I., Bordet R., Deplanque D., Al Khedr A., Richard F., Libersa C. and Pasquier F. (2005) Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 76, 16241629.
  • Masters C. L. and Beyreuther K. (1998) Alzheimer's disease. Br. Med. J. 316, 446448.
  • Masters C. L. and Beyreuther K. (2005) The neuropathology of Alzheimer's disease in the year 2005, in Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics (BealM. F., LangA. E. and LudolphA. C., eds), pp. 433440. Cambridge University Press, Cambridge.
  • Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L. and Beyreuther K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82, 42454249.
  • Mathis C. A., Bacskai B. J., Kajdasz S. T., et al. (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett. 12, 295298.
  • Mattson M. P. and Chan S. L. (2003) Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 34, 385397.
  • Mattson M. P., Tomaselli K. J. and Rydel R. E. (1993) Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res. 621, 3549.
  • Mayeux R., Saunders A. M., Shea S., et al. (1998) Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease: Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N. Engl. J. Med. 338, 506511.
  • Maynard C. J., Cappai R., Volitakis I., Cherny R. A., White A. R., Beyreuther K., Masters C. L., Bush A. I. and Li Q. X. (2002) Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 277, 44 67044 676.
  • McKhann G., Drachman D., Folstein M., Katzman R., Price D. and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939944.
  • McLaurin J., Cecal R., Kierstead M. E., et al. (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8, 12631269.
  • McLean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I. and Masters C. L. (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol 46, 860866.
  • Mecocci P., MacGarvey U. and Beal M. F. (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36, 747751.
  • Meda L., Cassatella M. A., Szendrei G. I., Otvos L., Baron P. Jr, Villalba M., Ferrari D. and Rossi F. (1995) Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374, 647650.
  • Mettenburg J. M., Arandjelovic S. and Gonias S. L. (2005) A chemically modified preparation of alpha2-macroglobulin binds beta-amyloid peptide with increased affinity and inhibits Abeta cytotoxicity. J. Neurochem. 93, 5362.
  • Michaelis M. L., Ansar S., Chen Y., Reiff E. R., Seyb K. I., Himes R. H., Audus K. L. and Georg G. I. (2005) {beta}-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J. Pharmacol. Exp. Ther. 312, 659668.
  • Miklossy J., Taddei K., Suva D., et al. (2003) Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease. Neurobiol. Aging 24, 655662.
  • Miura T., Suzuki K., Kohata N. and Takeuchi H. (2000) Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. Biochemistry 39, 70247031.
  • Mohanakrishnan P., Fowler A. H., Vonsattel J. P., Husain M. M., Jolles P. R., Liem P. and Komoroski R. A. (1995) An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp. Brain Res. 102, 503510.
  • Moir R. D., Atwood C. S., Romano D. M., Laurans M. H., Huang X., Bush A. I., Smith J. D. and Tanzi R. E. (1999) Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. Biochemistry 38, 45954603.
  • Moosmann B. and Behl C. (2002) Antioxidants as treatment for neurodegenerative disorders. Expert Opin. Invest. Drugs 11, 14071435.
  • Moreira P. I., Santos M. S., Sena C., Nunes E., Seica R. and Oliveira C. R. (2005) CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp. Neurol. 196, 112119.
  • Morihara T., Teter B., Yang F., Lim G. P., Boudinot S., Boudinot F. D., Frautschy S. A. and Cole G. M. (2005) Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology 30, 11111120.
  • Morris J. C. and Price A. L. (2001) Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci. 17, 101118.
  • Mucke L., Masliah E., Yu G. Q., et al. (2000) High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 40504058.
  • Mudher A. and Lovestone S. (2002) Alzheimer's disease – do tauists and baptists finally shake hands? Trends Neurosci. 25, 2226.
  • Mukrasch M. D., Biernat J., Von Bergen M., Griesinger C., Mandelkow E. and Zweckstetter M. (2005) Sites of Tau important for aggregation populate {beta}-structure and bind to microtubules and polyanions. J. Biol. Chem. 280, 24 97824 986.
  • Multhaup G., Schlicksupp A., Hesse L., Beher D., Ruppert T., Masters C. L. and Beyreuther K. (1996) The amyloid precursor protein of Alzheimer's disease in the reduction of copper (II) to copper (I). Science 271, 14061409.
  • Naslund J., Schierhorn A., Hellman U., et al. (1994) Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. U.S.A. 91, 83788382.
  • Necula M., Chirita C. N. and Kuret J. (2005) Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry 44, 10 22710 237.
  • Noble W., Planel E., Zehr C., et al. (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 69906995.
  • Nordberg A. (1993) In vivo detection of neurotransmitter changes in Alzheimer's disease. Ann. N.Y. Acad. Sc 695, 2733.
  • Nordberg A., Amberla K., Shigeta M., et al. (1998) Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis. Assoc. Disord. 12, 228237.
  • Okamura N., Suemoto T., Furumoto S., et al. (2005) Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J. Neurosci. 25, 10 85710 862.
  • Olson J. M., Goddard K. A. and Dudek D. M. (2001) The amyloid precursor protein locus and very-late-onset Alzheimer disease. Am. J. Hum. Genet. 69, 895899.
  • Opazo C., Huang X., Cherny R. A., et al. (2002) Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 277, 40 30240 308.
  • Padmanabhan G., Becue I., Smith J. A. (1989) Clioquinol, in: Analytical Profiles of Drug Substances (FloreyK, ed), pp. 5790. Academic Press, New York.
  • Pappolla M. A., Omar R. A., Kim K. S. and Robakis N. K. (1992) Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am. J. Pathol 140, 621628.
  • Parihar M. S. and Hemnani T. (2003) Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity. J. Biosci. 28, 121128.
  • Parker W. D. Jr, Parks J., Filley C. M. and Kleinschmidt-DeMasters B. K. (1994) Electron transport chain defects in Alzheimer's disease brain. Neurology 44, 10901096.
  • Parks J., Smith K. T. S., Trimmer P. A., Bennett J. P. Jr and Parker W. D. Jr (2001) Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J. Neurochem. 76, 10501056.
  • Patel N. V., Gordon M. N., Connor K. E., Good R. A., Engelman R. W., Mason J., Morgan D. G., Morgan T. E. and Finch C. E. (2005) Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol. Aging 26, 9951000.
  • Perl D. P. (2000) Neuropathology of Alzheimer's disease and related disorders. Neurol. Clin. 18, 847864.
  • Perry E. K., Tomlinson B. E., Blessed G., Bergmann K., Gibson P. H. and Perry R. H. (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 2, 14571459.
  • Petersen R. C., Smith G. E., Waring S. C., Ivnik R. J., Tangalos E. G. and Kokmen E. (1999) Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303308.
  • Petrella J. R., Coleman R. E. and Doraiswamy P. M. (2003) Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 226, 315336.
  • Phelps M. E. (2000) PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 41, 661681.
  • Phinney A. L., Drisaldi B., Schmidt S. D., et al. (2003) In vivo reduction of amyloid-beta by a mutant copper transporter. Proc. Natl. Acad. Sci. U.S.A. 100, 14 19314 198.
  • Pietrak B. L., Crouthamel M. C., Tugusheva K., et al. (2005) Biochemical and cell-based assays for characterization of BACE-1 inhibitors. Anal. Biochem. 342, 144151.
  • Piggott M. A., Owens J., O'Brien J., et al. (2003) Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. J. Chem. Neuroanat. 25, 161173.
  • Prasad K. N. A. R., Hovland W. C., Cole K. C., Prasad P. and Nahreini J., Edwards-Prasad and C. P. Andreatta (2000) Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale. Clin. Neuropharmacol. 23, 213.
  • Price J. C., Klunk W. E., Lopresti B. J., et al. (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow Metab. 25, 15281547.
  • Price J. L. and Morris J. C. (1999) Tangles and plaques in nondemented aging and preclinical Alzheimer's disease. Ann. Neurol. 45, 358368.
  • Puglielli L., Friedlich A. L., Setchell K. D., et al. (2005) Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J. Clin. Invest. 115, 25562563.
  • Qiao H., Koya R. C., Nakagawa K., Tanaka H., Fujita H., Takimoto M. and Kuzumaki N. (2005) Inhibition of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol. Aging 26, 849855.
  • Quélever G., Kachidian P., Melon C., Garino C., Laras Y., Pietrancosta N., Sheha M. and Louis Kraus J. (2005) Enhanced delivery of gamma-secretase inhibitor DAPT into the brain via an ascorbic acid mediated strategy. Org. Biomol. Chem. 3, 24502457.
  • Quinn J., Kulhanek D., Nowlin J., Jones R., Pratico D., Rokach J. and Stackman R. (2005) Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res. 1037, 209213.
  • Quintanilla R. A., Muñoz F. J., Metcalfe M. J., Hitschfeld M., Olivares G., Godoy J. A. and Inestrosa N. C. (2005) Trolox and 17{beta}-estradiol protect against amyloid {beta}-Peptide neurotoxicity by a mechanism that involves modulation of the Wnt signaling pathway. J. Biol. Chem. 280, 11 61511 625.
  • Racke M. M., Boone L. I., Hepburn D. L., et al. (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β. J. Neurosci. 25, 629636.
  • Raman B., Ban T., Yamaguchi K. I., Sakai M., Kawai T., Naiki H. and Goto Y. (2005) Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid beta peptide. J. Biol. Chem. 280, 16 15716 162.
  • Ramassamy C., Averill D., Beffert U., et al. (2000) Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol. Dis. 7, 2337.
  • Ramassamy C., Krzywkowski P., Averill D., Lussier-Cacan S., Theroux L., Christen Y., Davignon J. and Poirier J. (2001) Impact of apoE deficiency on oxidative insults and antioxidant levels in the brain. Brain Res. Mol. Brain Res. 86, 7683.
  • Ramírez B. G., Blázquez C., Gómez del Pulgar T., Guzmán M. and De Ceballos M. L. (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25, 19041913.
  • Rapoport M., Dawson H. N., Binder L. I., Vitek M. P. and Ferreira A. (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 99, 63646369.
  • Refolo L. M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G. S., Sambamurti K., Duff K. and Pappolla M. A. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321331.
  • Refolo L. M., Pappolla M. A., LaFrancois J., et al. (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8, 890899.
  • Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S. and Mobius H. J. (2003) Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 13331341.
  • Rezai-Zadeh K., Shytle D., Sun N., et al. (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 25, 88078814.
  • Ritchie C. W., Bush A. I., Mackinnon A., et al. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60, 16851691.
  • Rodriguez-Martin T., Garcia-Blanco M. A., Mansfield S. G., Grover A. C., Hutton M., Zhou Q., Yu J., Anderton B. H. and Gallo J. M. (2005) Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. Proc. Natl. Acad. Sci. U.S.A. 102, 15 65915 664.
  • Rogaev E. I., Sherrington R., Rogaeva E. A., et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775778.
  • Rogawski M. A. and Wenk G. L. (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 9, 275308.
  • Rogers J., Schultz J., Brachova L., Lue L. F., Webster S., Bradt B., Cooper N. R. and Moss D. E. (1992) Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease. Res. Immunol. 143, 624630.
  • Roher A. E., Chaney M. O., Kuo Y. M., et al. (1996) Morphology and toxicity of Abeta-(1–42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271, 20 63120 635.
  • Rose S. E., Chen F., Chalk J. B., Zelaya F. O., Strugnell W. E., Benson M., Semple J. and Doddrell D. M. (2000) Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J. Neurol. Neurosurg. Psychiatry 69, 528530.
  • Rossjohn J., Cappai R., Feil S. C., et al. (1999) Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat Struct. Biol. 6, 327331.
  • Rovelet-Lecrux A., Hannequin D., Raux G., et al. (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 2426.
  • Sair H. I., Doraiswamy P. M. and Petrella J. R. (2004) In vivo amyloid imaging in Alzheimer's disease. Neuroradiology 46, 93104.
  • Saito T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S. M., Suemoto T., Higuchi M. and Saido T. C. (2005) Somatostatin regulates brain amyloid beta peptide Abeta (42) through modulation of proteolytic degradation. Nat. Med. 11, 434439.
  • Sakaue F., Saito T., Sato Y., Asada A., Ishiguro K., Hasegawa M. and Hisanaga S. (2005) Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, 25, or p39. J. Biol. Chem. 280, 31 52231 529.
  • Sano M., Ernesto C., Thomas R. G., et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336, 12161222.
  • Santacruz K., Lewis J., Spires T., et al. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476481.
  • Santa-María I., Hernández F., Smith M. A., Perry G., Avila J. and Moreno F. J. (2005) Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers. Mol. Cell Biochem. 278, 203212.
  • Satlin A., Bodick N., Offen W. W. and Renshaw P. F. (1997) Brain proton magnetic resonance spectroscopy (H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am. J. Psychiatry 154, 14591461.
  • Sato K., Higuchi M., Iwata N., Saido T. C. and Sasamoto K. (2004) Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur. J. Med. Chem. 39, 573578.
  • Sato T., Tanimura Y., Hirotani N., Saido T. C., Morishima-Kawashima M. and Ihara Y. (2005) Blocking the cleavage at midportion between gamma- and epsilon-sites remarkably suppresses the generation of amyloid beta-protein. FEBS Lett.. 579, 29072912.
  • Saunders A. M., Strittmatter W. J., Schmechel D., et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 14671472.
  • Saura C. A., Chen G., Malkani S., et al. (2005) Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J. Neurosci. 25, 67556764.
  • Sayre L. M., Perry G., Harris P. L., Liu Y., Schubert K. A. and Smith M. A. (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J. Neurochem. 74, 270279.
  • Scheltens P. H. (2001) Structural neuroimaging of Alzheimer's disease and other dementias. Aging 13, 203209.
  • Schenk D. (2002) Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev. Neurosci. 3, 824828.
  • Schenk D., Hagen M. and Seubert P. (2004) Current progress in beta-amyloid immunotherapy. Curr. Opin. Immunol. 16, 599606.
  • Scherzer C. R., Offe K., Gearing M., et al. (2004) Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch. Neurol. 61, 12001205.
  • Scheuner D., Eckman C., Jensen M., et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864870.
  • Schippling S., Kontush A., Arlt S., Buhmann C., Sturenburg H. J., Mann U., Muller-Thomsen T. and Beisiegel U. (2000) Increased lipoprotein oxidation in Alzheimer's disease. Free Radic. Biol. Med. 28, 351360.
  • Schuff N., Capizzano A. A., Du A. T., et al. (2002) Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 58, 928935.
  • Schuster D., Rajendran A., Hui S. W., Nicotera T., Srikrishnan T. and Kruzel M. L. (2005) Protective effect of colostrinin on neuroblastoma cell survival is due to reduced aggregation of beta-amyloid. Neuropeptides 39, 419426.
  • Selkoe D. J. (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741766.
  • Selkoe D. J. (2002) Alzheimer's disease is a synaptic failure. Science 298, 789791.
  • Selley M. L., Close D. R. and Stern S. E. (2002) The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol. Aging 23, 383388.
  • Seubert P., Vigo-Pelfrey C., Esch F., et al. (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325327.
  • Seubert P., Oltersdorf T., Lee M. G., et al. (1993) Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature 361, 260263.
  • Sherrington R., Rogaev E. I., Liang Y., et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754760.
  • Shi J., Perry G., Berridge M. S., Aliev G., Siedlak S. L., Smith M. A., LaManna J. C. and Friedland R. P. (2002) Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J. Nucl. Med. 43, 10441051.
  • Shie F. S. M., Montine K. S., Breyer R. M. and Montine T. J. (2005) Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons. Brain Pathol. 15, 134138.
  • Shimadzu H., Suemoto T., Suzuki M., Shiomitsu T., Okamura N., Kudo Y. and Sawada T. (2003) A novel probe for imaging amyloid-β: Synthesis of F-18 labelled BF-108, an Acridine Orange analog. J. Labelled Comp. Radiopharm. 46, 765772.
  • Shoghi-Jadid K., Small G. W., Agdeppa E. D., et al. (2002) Localisation of neurofibrillary tangles and β-amyloid plaques in the brains of living patients with Alzheimer's disease. Am. J. Geriatr. Psychiatry 10, 2435.
  • Si M. L., Long C., Yang D. I., Chen M. F. and Lee T. J. (2005) Statins prevent beta-amyloid inhibition of sympathetic alpha7-nAChR-mediated nitrergic neurogenic dilation in porcine basilar arteries. J. Cereb. Blood Flow Metab. 25, 15731585.
  • Siemers E., Skinner M., Dean R. A., Gonzales C., Satterwhite J., Farlow M., Ness D. and May P. C. (2005) Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol. 28, 126132.
  • Siemers E. R., Quinn J. F., Kaye J., et al. (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602604.
  • Silverman D. H. and Phelps M. E. (2001) Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: normal development, aging, dementia, and stroke. Mol. Genet. Metab. 74, 128138.
  • Silverman D. H., Small G. W., Chang C. Y., et al. (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286, 21202127.
  • Singer O., Marr R. A., Rockenstein E., Crews L., Coufal N. G., Gage F. H., Verma I. M. and Masliah E. (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8, 13431349.
  • Small D. H., Nurcombe V., Reed G., Clarris H., Moir R. and Beyreuther K. and Masters C. L. (1994) A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J. Neurosci. 14, 21172127.
  • Smith D. P., Smith D. G., Curtain C. C., et al. (2006) Copper mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J Biol Chem.[Epub ahead of print].
  • Smith M. A., Sayre L. M., Vitek M. P., Monnier V. M. and Perry G. (1995) Early AGEing and Alzheimer's. Nature 374, 316.
  • Smith M. A., Harris P. L., Sayre L. M. and Perry G. (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U.S.A. 94, 98669868.
  • Smith M. J., Kwok J. B., McLean C. A., et al. (2001) Variable phenotype of Alzheimer's disease with spastic paraparesis. Ann. Neurol. 49, 125129.
  • Snyder E. M., Nong Y., Almeida C. G., et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 8, 10511058.
  • Spillantini M. G., Bird T. D. and Ghetti B. (1998) Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol. 8, 387402.
  • Spina M. B., Squinto S. P., Miller J., Lindsay R. M. and Hyman C. (1992) Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem. 59, 99106.
  • St George-Hyslop P. H. (2000) Genetic factors in the genesis of Alzheimer's disease. Ann. N.Y. Acad. Sci. 924, 17.
  • St George-Hyslop P., McLachlan D. C., Tsuda T., Rogaev E., Karlinsky H., Lippa C. F., Pollen D. and Tuda T. (1994) Alzheimer's disease and possible gene interaction. Science 263, 537.
  • Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S. and Roses A. D. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90, 19771981.
  • Sultana R., Ravagna A., Mohmmad-Abdul H., Calabrese V. and Butterfield D. A. (2005) Ferulic acid ethyl ester protects neurons against amyloid beta- peptide (1–42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J. Neurochem. 92, 749758.
  • Sunderland T., Linker G., Mirza N., et al. (2003) Decreased beta-amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 20942103.
  • Swerdlow R. H., Parks J. K., Cassarino D. S., Maguire D. J., Maguire R. S., Bennett J. P. Jr, Davis R. E. and Parker W. D. Jr (1997) Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 49, 918925.
  • Takahashi S., Takahashi I., Sato H., Kubota Y., Yoshida S. and Muramatsu Y. (2001) Age-related changes in the concentrations of major and trace elements in the brain of rats and mice. Biol. Trace Elem. Res. 80, 145158.
  • Tamagno E., Robino G., Obbili A., Bardini P., Aragno M., Parola M. and Danni O. (2003) H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp. Neurol. 180, 144155.
  • Tang B. L. (2005) Alzheimer's disease: channeling APP to non-amyloidogenic processing. Biochem. Biophys. Res. Commun. 331, 375378.
  • Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M. and Hasegawa M. (2005) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280, 76147623.
  • Terry R. D., Masliah E. and Hansen L. A. (1994) Structural basis of the cognitive alterations, in Alzheimer Disease (TerryR. D., KatzmanR. and BickK. L., eds). Raven Press, New York.
  • Thompson P. M., Hayashi K. M., De Zubicaray G. I., et al. (2004) Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage 22, 17541766.
  • Van Dam D., Abramowski D., Staufenbiel M. and De Deyn P. P. (2005) Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl) 180, 177190.
  • Vanhoutte G., Dewachter I., Borghgraef P., Van Leuven F. and Van der Linden A. (2005) Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn. Reson. Med. 53, 607613.
  • Villemagne V. L., Ackermann U., Gong S. J., et al. (2005a) Abeta amyloid imaging in dementia with Lewy bodies and Alzheimer's disease with 11C-PIB PET. J. Nucl. Med. 46, 124P.
  • Villemagne V. L., Rowe C. C., Macfarlane S. and Novakovic K. and Masters C. L. (2005b) Imaginem Oblivionis: The prospects of neuroimaging for early detection of Alzheimer's disease. J. Clin. Neurosci. 12, 221230.
  • Wadghiri Y. Z., Sigurdsson E. M., Wisniewski T. and Turnbull D. H. (2005) Magnetic resonance imaging of amyloid plaques in transgenic mice. Meth Mol Biol. 299, 365379.
  • Walker L. C., Price D. L., Voytko M. L. and Schenk D. B. (1994) Labelling of cerebral amyloid in vivo with a monoclonal antibody. J. Neuropathol. Exp. Neurol. 53, 377383.
  • Walker Z., Costa D. C., Walker R. W., et al. (2002) Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J. Neurol. Neurosurg. Psychiatry 73, 134140.
  • Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., Rowan M. J. and Selkoe D. J. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535539.
  • Wang J., Ho L., Qin W., et al. (2005) Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J. 19, 659661.
  • Wang Y. and Ha Y. (2004) The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain. Mol. Cell 15, 343353.
  • Weidemann A., Konig G., Bunke D., Fischer P., Salbaum J. M., Masters C. L. and Beyreuther K. (1989) Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 57, 115126.
  • Weiner H. L., Lemere C. A., Maron R., Spooner E. T., Grenfell T. J., Mori C., Issazadeh S., Hancock W. W. and Selkoe D. J. (2000) Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48, 567579.
  • White A. R., Reyes R., Mercer J. F., et al. (1999) Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 842, 439444.
  • Wilcock D. M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K. E., Gordon M. N. and Morgan D. (2003) Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23, 37453751.
  • Wolfe M. S. (2002) Therapeutic strategies for Alzheimer's disease. Nat. Rev. Drug Discov. 1, 859866.
  • Wolozin B., Kellman W., Ruosseau P., Celesia G. G. and Siegel G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 14391443.
  • Woltjer R. L., Nghiem W., Maezawa I., Milatovic D., Vaisar T., Montine K. S. and Montine T. J. (2005) Role of glutathione in intracellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity. J. Neurochem. 93, 10471056.
  • Wong G. T., Manfra D., Poulet F. M., et al. (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12 87612 882.
  • Xia W. (2003) Amyloid inhibitors and Alzheimer's disease. Curr. Opin. Invest. Drugs 4, 5559.
  • Xie J. and Guo Q. (2005) PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein. J. Biol. Chem. 280, 13 82413 832.
  • Xie Z., Romano D. M. and Tanzi R. E. (2005) Effects of RNAi-mediated silencing of PEN-2, APH-1a, and nicastrin on wild-type vs FAD mutant forms of presenilin 1. J. Mol. Neurosci. 25, 6778.
  • Xu H., Gouras G. K., Greenfield J. P., et al. (1998) Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat. Med. 4, 447451.
  • Xu H., Faber C., Uchiki T., Racca J. and Dealwis C. (2006) Structures of eukaryotic ribonucleotide reductase I define gemcitabine diphosphate binding and subunit assembly. Proc. Natl. Acad. Sci. U.S.A. 103, 40284033.
  • Xu Y., Jack C. R. J., O'Brien P. C., Kokmen E., Smith G. E., Ivnik R. J., Boeve B. F., Tangalos R. G. and Petersen R. C. (2000) Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 54, 17601767.
  • Yamada K. T. M., Kamei H., Nagai T., Dohniwa M., Kobayashi K., Yoshida S., Ohhara T., Takauma K. and Nabeshima T. (2005) Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats. Behav. Brain Res. 162, 191199.
  • Yamamoto K., Ishikawa T., Sakabe T., Taguchi T., Kawai S. and Marsala M. (1998) The hydroxyl radical scavenger Nicaraven inhibits glutamate release after spinal injury in rats. Neuroreport 9, 16551659.
  • Yamamoto N., Yokoseki T., Shibata M., Yamaguchi H. and Yanagisawa K. (2005) Suppression of Abeta deposition in brain by peripheral administration of Fab fragments of anti-seed antibody. Biochem. Biophys. Res. Commun. 335, 4547.
  • Yang F., Lim G. P., Begum A. N., et al. (2005) Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 58925901.
  • Yang S. P., Kwon B. O., Gho Y. S. and Chae C. B. (2005) Specific interaction of VEGF165 with beta-amyloid, and its protective effect on beta-amyloid-induced neurotoxicity. J. Neurochem. 93, 118127.
  • Ye L., Morgenstern J. L., Gee A. D., Hong G., Brown J. and Lockhart A. (2005) Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J. Biol. Chem. 280, 23 59923 604.
  • Yoshiike Y., Tanemura K., Murayama O., Akagi T., Murayama M., Sato S., Sun X., Tanaka N. and Takashima A. (2001) New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity. J. Biol. Chem. 276, 32 29332 299.
  • Youm J. W., Kim H., Han J. H., et al. (2005) Transgenic potato expressing Abeta reduce Abeta burden in Alzheimer's disease mouse model. FEBS Lett. 579, 67376744.
  • Yue X., Lu M., Lancaster T., et al. (2005) Brain estrogen deficiency accelerates A{beta} plaque formation in an Alzheimer's disease animal model. Proc. Natl. Acad. Sci. U.S.A. 102, 19 19819 203.
  • Zhang J., Yarowsky P., Gordon M. N., Di Carlo G., Munireddy S., Van Zijl P. C. and Mori S. (2004) Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn. Reson. Med. 51, 452457.
  • Zhang W., Oya S., Kung M. P., Hou C., Maier D. L. and Kung H. F. (2005) F-18 polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl. Med. Biol. 32, 799809.
  • Zimmermann M., Gardoni F., Marcello E., Colciaghi F., Borroni B., Padovani A., Cattabeni F. and Di Luca M. (2004) Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J. Neurochem. 90, 14891499.
  • Zimmermann M., Borroni B., Cattabeni F., Padovani A. and Di Luca M. (2005) Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol. Dis. 19, 237242.